Comparative Efficacy and Safety Study of RGB-14-P and Prolia in Women With Postmenopausal Osteoporosis
Status:
Recruiting
Trial end date:
2023-10-30
Target enrollment:
Participant gender:
Summary
This study will be conducted to assess the efficacy, pharmacodynamic (PD), safety,
tolerability, and immunogenicity of RGB -14- P compared to US-licensed Prolia® in
participants with postmenopausal osteoporosis, in a comparative manner.